Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Roche

Blood test could ‘reliably rule out’ Alzheimer’s, trial finds

There are hopes it will offer reassurance to patients with cognitive decline and help them avoid unnecessary further testing, researchers said.

Evening Standard

Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations

Roche stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.

Investors Business Daily

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review

The stock market rally revived with the major indexes reclaiming key levels and many top leaders flashing buy signals.

Investors Business Daily

If You Hate Getting Pap Smears, Here’s Some Extremely Good News

The first self-administered tests for collecting vaginal samples are on the way to health care facilities, making Pap smears more accessible and tolerable.

Inverse

Read news from The Economist, FT, and more,
with one subscription

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter

TG Therapeutics stock broke out Monday less than two weeks after the biotech company reported a surprise profit for the June quarter.

Investors Business Daily

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Fortune

AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment

AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.

Investors Business Daily

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review

The stock market rally had some wild moves during the week. The Dow Jones and Russell 2000 jumped, but came off highs. The Nasdaq tumbled.

Investors Business Daily

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

Investors Business Daily

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

How To Find the Best European Stocks To Buy

European stocks are cheaper than their U.S. counterparts and there are plenty of high-quality companies to choose from. Here's how to find them.

LiveScience

1st-of-its-kind Parkinson's treatment may slow aggressive disease, trial hints

A new antibody drug for Parkinson's disease appears to slow the progression of its movement-related symptoms, at least in some patients.

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Revolutionary Antibiotic Breakthrough: Tackling Deadly Drug-Resistant Bacteria!

Researchers make strides in the battle against antibiotic resistance with a potential new class of drugs to combat drug-resistant bacteria, like CRAB.

Investors Business Daily

Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker

Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs.

The Conversation

Miniature organs on chips could revolutionize health-care research

To understand how bodies work, medical researchers and scientists have created mini models of organs, called organoids. This field of scientific research has had profound impacts on biological discovery and pharmaceutical development.

Investors Business Daily

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

The Street

Roivant higher as Vivek Ramaswamy-found firm sells bowel disease drug for $7.1 billion

Roivant, the drug developer founded by Republican Presidential candidate Vivek Ramaswamy, has sold the rights to its bowel disease treatment for $7.1 billion.

Investors Business Daily

Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance

Roche stock skidded early Thursday after the Swiss drugmaker said declining demand for Covid products weighed on third-quarter sales.

The Guardian - UK

Patients in England will be first to access seven-minute cancer treatment jab

NHS is first health system to offer injection to hundreds of patients which will cut treatment times by up to three quarters

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.